St. John Morgan

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.